Payment overview · 2025
General Payments
$336.42
12 reported records · 6 companies
Healthcare provider profile · identity verified
David Vizel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1508809856
Verified facts
What the public records show
CMS Open Payments records show David Vizel, M.D. received $336.42 in general payments during 2025 across 12 reported records.
Aimmune Therapeutics, Inc. accounted for 43.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Zenpep by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $147.33 | 43.8% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.96 | 26.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.97 | 9.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.72 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.16 | 7.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.28 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $336.42 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $147.33 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $87.96 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 196 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
240 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
293 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
196 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 752 | 84 |
| Hydralazine Hcl | Hydralazine Hcl | 620 | 65 |
| Ezetimibe | Ezetimibe | 579 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 529 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 505 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 45 |
| Mirtazapine | Mirtazapine | 420 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 44 |
| Famotidine | Famotidine | 386 | 44 |
| Losartan Potassium | Losartan Potassium | 341 | 44 |
| Dexlansoprazole Dr | Dexlansoprazole | 329 | 38 |
| Metformin Hcl | Metformin Hcl | 324 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 322 | 39 |
| Memantine Hcl | Memantine Hcl | 315 | 41 |
| Entresto | Sacubitril/Valsartan | 293 | 32 |
| Carvedilol | Carvedilol | 273 | 32 |
| Furosemide | Furosemide | 260 | 29 |
| Linzess | Linaclotide | 240 | 28 |
| Spironolactone | Spironolactone | 228 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 224 | 28 |
| Donepezil Hcl | Donepezil Hcl | 220 | 29 |
| Sucralfate | Sucralfate | 207 | 22 |
| Ozempic | Semaglutide | 196 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 194 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 187 | 22 |
| Trazodone Hcl | Trazodone Hcl | 186 | 23 |
| Febuxostat | Febuxostat | 172 | 19 |
| Atenolol | Atenolol | 162 | 23 |
| Praluent Pen | Alirocumab | 162 | 39 |
| Sertraline Hcl | Sertraline Hcl | 155 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 152 | 15 |
| Azelastine Hcl | Azelastine Hcl | 144 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 19 |
| Montelukast Sodium | Montelukast Sodium | 140 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 15 |
| Diclofenac Epolamine | Diclofenac Epolamine | 135 | 14 |
| Eliquis | Apixaban | 135 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 131 | 25 |
| Repatha Sureclick | Evolocumab | 129 | 23 |
| Jardiance | Empagliflozin | 127 | 18 |
| Lidocaine | Lidocaine | 125 | 16 |
| Clonidine | Clonidine | 122 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 14 |
| Allopurinol | Allopurinol | 117 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 13 |
| Bupropion Xl | Bupropion Hcl | 105 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 20 |
| Potassium Chloride | Potassium Chloride | 102 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 101 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 50 |
| Finasteride | Finasteride | 91 | 15 |
| Myrbetriq | Mirabegron | 88 | 16 |
| Olanzapine | Olanzapine | 81 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 81 | suppressed |
| Creon | Lipase/Protease/Amylase | 79 | 11 |
| Meclizine Hcl | Meclizine Hcl | 79 | 12 |
| Trulicity | Dulaglutide | 78 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 77 | 13 |
| Nateglinide | Nateglinide | 73 | 11 |
| Vascepa | Icosapent Ethyl | 73 | 11 |
| Edarbi | Azilsartan Medoxomil | 71 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 71 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 70 | suppressed |
| Omeprazole | Omeprazole | 68 | 11 |
| Methylprednisolone | Methylprednisolone | 66 | 46 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 63 | suppressed |
| Valsartan | Valsartan | 59 | suppressed |
| Nitroglycerin | Nitroglycerin | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 54 | suppressed |
| Repatha Syringe | Evolocumab | 54 | 14 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 52 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 48 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | suppressed |
| Lisinopril | Lisinopril | 47 | suppressed |
| Metronidazole | Metronidazole | 47 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Irbesartan | Irbesartan | 45 | suppressed |
| Ketoconazole | Ketoconazole | 45 | suppressed |
| Dutasteride | Dutasteride | 44 | suppressed |
| Cilostazol | Cilostazol | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Telmisartan | Telmisartan | 41 | suppressed |
| Rivastigmine | Rivastigmine | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 14 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Ursodiol | Ursodiol | 33 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Captopril | Captopril | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Tadalafil | Tadalafil | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Nadolol | Nadolol | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Pimecrolimus | Pimecrolimus | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 14 |
| Steglatro | Ertugliflozin Pidolate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Repaglinide | Repaglinide | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amitiza | Lubiprostone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Vesicare | Solifenacin Succinate | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Diovan | Valsartan | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $336.42 · 12 records | Aimmune Therapeutics, Inc. | BOTOX, Kerendia, LEQVIO, Ozempic, VOQUEZNA, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error